Previous 10 | Next 10 |
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +98%. Edesa (NASDAQ:EDSA) +68%. Sentage (NASDAQ:SNTG) +21%. Viveve (NASDAQ:VIVE) +19%. Aterian (NASDAQ:ATER) +15%. Atea Pharmaceuticals (NASDAQ:AVIR) +12%. Corvus (NASDAQ:CRVS) +13%. Five Star (NASDAQ:FVE) +12%. BEST (NYSE:BEST) +10%. Petros Pharmaceutic...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +155%, Edesa Biotech (NASDAQ:EDSA) +34%, Atea Pharmaceuticals (NASDAQ:AVIR) +20%, Synlogic (NASDAQ:SYBX) +13%, Viveve Medical (NASDAQ:VIVE) +9%. Losers: BeyondSpring (NASDAQ:BYSI) -22%, Protagonist Therap...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks touched their lowest levels in four weeks Friday as inflation fears took hold and a range of Chinese economic indicators pointed to a ...
COVID boost shots and drug development marked crucial themes in Friday's trading as a closely watched U.S. government panel met and backed a third COVID vaccine shot for certain Americans. COVID vaccine makers BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) all lost ground...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid some rather impressive volatility today, Protagonist Therapeutics (NASDAQ: PTGX ) is one of the biggest stock market losers. At one point today, this stock lost more than two-thirds of its value in one swoop...
Shares of Protagonist Therapeutics (NASDAQ: PTGX) , a clinical-stage biotechnology company, are plummeting today. As of 2:26 p.m. EDT, the stock price has fallen 62.9% in response to news of a clinical hold from the FDA. Protagonist Therapeutics is advancing an ambitious pipelin...
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) has reported that its investigational product candidate in development, rusfertide has been put on a clinical hold. The FDA notified Protagonist Therapeutics of a non-clinical finding in a 26-week rasH2 transgenic mouse model...
Protagonist Therapeutics (NASDAQ:PTGX) -53% after FDA placed clinical hold on rusfertide studies Offerpad Solutions (NYSE:OPAD) -17%. IronNet (NYSE:IRNT) -10%. AEye (NASDAQ:LIDR) -8%. ION Geophysical (NYSE:IO) -6%. For further details see: IronNet, Protagonist Therapeutics amo...
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program PR Newswire NEWARK, Calif. , Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of...
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology Renowned Expert in Gastrointestinal Diseases Joins Company to Lead the Advancement and Expansion of Its Pipeline PR Newswire NEWARK, Calif. , Se...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...